Table 1.
Participant characteristics at baseline survey by change in household income for women in the Young and Strong trial in 2012–2013
| Change in Household Income | |||||
|---|---|---|---|---|---|
| Maintain ≥ $100,000 (N = 132) |
Same < $100,000 (N = 115) |
Gained (N = 54) | Lost (N = 55) | ||
| N. (%) | N. (%) | N. (%) | N. (%) | p value | |
| Demographics | |||||
| Age | 0.16 | ||||
| < 35 | 18 (13.6) | 30 (26.1) | 13 (24.1) | 15 (27.3) | |
| 35–39 | 38 (28.8) | 23 (20.0) | 15 (27.8) | 11 (20.0) | |
| 40–45 | 76 (57.6) | 62 (53.9) | 26 (48.2) | 29 (52.7) | |
| Education | < 0.0001a | ||||
| ≤ High School | 1 (0.8) | 13 (11.3) | 11 (20.4) | 10 (18.2) | |
| ≥ Some College | 131 (99.2) | 102 (88.7) | 43 (79.6) | 45 (81.8) | |
| Married | < 0.0001 | ||||
| Yes | 122 (92.4) | 82 (71.3) | 43 (79.6) | 41 (74.6) | |
| No | 10 (7.6) | 33 (28.7) | 11 (20.4) | 14 (25.5) | |
| Children | 0.07 | ||||
| Yes | 107 (81.1) | 78 (67.8) | 36 (67.7) | 40 (74.1) | |
| No | 25 (18.9) | 37 (32.2) | 18 (33.3) | 14 (25.9) | |
| Race/Ethnicity | 0.31 | ||||
| Non-Hispanic, White | 108 (81.8) | 85 (74.6) | 38 (70.4) | 41 (74.6) | |
| Hispanic, Black, Other | 24 (18.2) | 29 (25.4) | 16 (29.6) | 14 (25.5) | |
| Region | 0.19 | ||||
| Northeast | 38 (28.8) | 30 (26.1) | 11 (20.4) | 12 (21.8) | |
| South/Southeast | 22 (16.7) | 34 (29.6) | 18 (33.3) | 18 (32.7) | |
| Midwest | 46 (34.9) | 38 (33.0) | 15 (27.8) | 18 (32.7) | |
| West | 26 (19.7) | 13 (11.3) | 10 (18.5) | 7 (12.7) | |
| Change in Employment | 0.23a | ||||
| None-Employed | 85 (68.0) | 66 (62.3) | 26 (54.2) | 33 (63.5) | |
| None-Unemployed | 20 (16.0) | 20 (18.9) | 11 (22.9) | 15 (28.9) | |
| Lost | 1 (0.8) | 0 (0.0) | 1 (2.1) | 0 (0.0) | |
| Gained | 19 (15.2) | 20 (18.9) | 10 (20.8) | 4 (7.7) | |
| Household Income | < 0.0001 | ||||
| < $50,000 | 0 (0.0) | 32 (27.8) | 37 (68.5) | 23 (41.8) | |
| $50,000–$99,999 | 0 (0.0) | 83 (72.2) | 17 (31.5) | 21 (38.2) | |
| ≥ $100,000 | 132 (100.0) | 0 (0.0) | 0 (0.0) | 11 (20.0) | |
| Cancer | |||||
| Stage | 0.01 | ||||
| I | 62 (47.0) | 39 (33.9) | 12 (22.2) | 14 (25.5) | |
| II | 54 (40.9) | 61 (53.0) | 31 (57.4) | 28 (50.9) | |
| III | 16 (12.1) | 15 (13.0) | 11 (20.4) | 13 (23.6) | |
| Estrogen Receptor | 0.19 | ||||
| Positive | 107 (81.1) | 82 (71.3) | 37 (68.5) | 40 (72.7) | |
| Negative | 25 (18.9) | 33 (28.7) | 17 (31.5) | 15 (27.3) | |
| Progesterone Receptor | 0.39 | ||||
| Positive | 99 (75.0) | 79 (68.7) | 36 (66.7) | 35 (63.6) | |
| Negative | 33 (25.0) | 36 (31.3) | 18 (33.3) | 20 (36.4) | |
| HER2 | 0.91 | ||||
| Positive | 30 (23.1) | 26 (22.8) | 12 (22.2) | 15 (27.3) | |
| Negative | 100 (76.9) | 88 (77.2) | 42 (77.8) | 40 (72.7) | |
| Baseline Cancer Treatment | |||||
| Chemotherapy | 0.01 | ||||
| Yes/Planned | 96 (73.3) | 97 (85.8) | 48 (88.9) | 48 (88.9) | |
| No | 35 (26.7) | 16 (14.2) | 6 (11.1) | 6 (11.1) | |
| Radiation | 0.05 | ||||
| Yes/Planned | 69 (61.6) | 59 (64.8) | 39 (83.0) | 31 (72.1) | |
| No | 43 (38.4) | 32 (35.2) | 8 (17.0) | 12 (27.9) | |
| Endocrine Therapy | 0.53 | ||||
| Yes/Planned | 97 (78.9) | 78 (72.2) | 34 (69.4) | 37 (74.0) | |
| No | 26 (21.1) | 30 (27.8) | 15 (30.6) | 13 (26.0) | |
| Baseline Psychosocial Measures | |||||
| Stress | 0.15a | ||||
| Low | 52 (40.3) | 42 (37.8) | 16 (30.2) | 14 (26.4) | |
| Moderate | 73 (56.6) | 61 (55.0) | 32 (60.4) | 32 (60.4) | |
| High | 4 (3.1) | 8 (7.2) | 5 (9.4) | 7 (13.2) | |
| Anxiety | 0.73 | ||||
| Normal | 55 (42.0) | 50 (43.9) | 19 (35.9) | 20 (37.7) | |
| Borderline | 31 (23.7) | 29 (25.4) | 11 (20.8) | 16 (30.2) | |
| Anxiety | 45 (34.4) | 35 (30.7) | 23 (42.4) | 17 (32.1) | |
| Depression | 0.03 | ||||
| No | 85 (68.6) | 63 (58.3) | 27 (54.0) | 23 (46.0) | |
| Yes | 39 (31.5) | 45 (41.7) | 23 (46.6) | 27 (54.0) | |
(a)Fisher’s exact test; N=Number; missing: 1 children, 1 race/ethnicity, 25 employment, 3 HER2, 4 chemotherapy, 63 radiation, 26 endocrine therapy, 10 stress, 5 anxiety, 24 depression; 100% had/planned surgery; p -values were calculated using chi-square tests or Fisher’s exact tests (when ≤5 women)